Related references
Note: Only part of the references are listed.Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer The STIC CTC Randomized Clinical Trial
Francois-Clement Bidard et al.
JAMA ONCOLOGY (2021)
Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages
Nicolas Guibert et al.
EUROPEAN RESPIRATORY REVIEW (2020)
Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group
Eric Faulkner et al.
VALUE IN HEALTH (2020)
Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS z480 and BEAMing
D. C. L. Vessies et al.
SCIENTIFIC REPORTS (2020)
The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review
Frederik van Delft et al.
CANCERS (2020)
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M. C. Liu et al.
ANNALS OF ONCOLOGY (2020)
Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019
Michael P. Douglas et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper
Arvind Dasari et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Detection of ctDNA with Personalized Molecular Barcode NGS and Its Clinical Significance in Patients with Early Breast Cancer
Tetsuhiro Yoshinami et al.
TRANSLATIONAL ONCOLOGY (2020)
Evaluating the Use of microRNA Blood Tests for Gastric Cancer Screening in a Stratified Population-Level Screening Program: An Early Model-Based Cost-Effectiveness Analysis
Ritika Kapoor et al.
VALUE IN HEALTH (2020)
Non-invasive early detection of cancer four years before conventional diagnosis using a blood test
Xingdong Chen et al.
NATURE COMMUNICATIONS (2020)
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Nicholas C Turner et al.
LANCET ONCOLOGY (2020)
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNu-1 trial
Enrique Aranda et al.
ESMO OPEN (2020)
Analysis of the Cost-Effectiveness of Liquid Biopsy to Determine Treatment Change in Patients with Her2-Positive Advanced Breast Cancer in Colombia
Diana Sanchez-Calderon et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2020)
Circulating tumor DNA and liquid biopsy in oncology
David W. Cescon et al.
NATURE CANCER (2020)
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study
Jeanne Tie et al.
GUT (2019)
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
J. H. Lee et al.
ANNALS OF ONCOLOGY (2019)
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
L. Tan et al.
ANNALS OF ONCOLOGY (2019)
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
Massimo Cristofanilli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Klaus Pantel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma
Emil Christensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing
Zandra C. Deans et al.
VIRCHOWS ARCHIV (2019)
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer
B. Lee et al.
ANNALS OF ONCOLOGY (2019)
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
C. M. Parseghian et al.
ANNALS OF ONCOLOGY (2019)
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
Jeanne Tie et al.
JAMA ONCOLOGY (2019)
Current and future perspectives of liquid biopsies in genomics-driven oncology
Ellen Heitzer et al.
NATURE REVIEWS GENETICS (2019)
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Jason D. Merker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Joshua D. Cohen et al.
SCIENCE (2018)
Health economic impact of liquid biopsies in cancer management
Maarten J. IJzerman et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2018)
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer
Semini Sumanasuriya et al.
EUROPEAN UROLOGY ONCOLOGY (2018)
Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management
Maha Elazezy et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2018)
What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
Reyes Bernabe et al.
EUROPEAN JOURNAL OF CANCER (2017)
Circulating tumor cells: clinical validity and utility
Luc Cabel et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility
A. M. Sofie Berghuis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al.
NATURE (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature
Maarten J. IJzerman et al.
PHARMACOECONOMICS (2017)
Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer
Koen Degeling et al.
VALUE IN HEALTH (2017)
Liquid biopsy genotyping in lung cancer: ready for clinical utility?
Wei-Lun Huang et al.
ONCOTARGET (2017)
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan et al.
NATURE REVIEWS CANCER (2017)
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Wolfgang J. Janni et al.
CLINICAL CANCER RESEARCH (2016)
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
David Lorente et al.
EUROPEAN UROLOGY (2016)
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Jeanne Tie et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
M. P. Morelli et al.
ANNALS OF ONCOLOGY (2015)
Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer
Matthew G. Krebs et al.
CLINICAL COLORECTAL CANCER (2015)
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Isaac Garcia-Murillas et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification
Alison S. Devonshire et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2014)
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
Amir Goldkorn et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
Jeffrey B. Smerage et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline
Natasha B. Leighl et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A New Model for Reimbursing Genome-Based Cancer Care
Scott D. Ramsey et al.
ONCOLOGIST (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine
Adrian Towse et al.
VALUE IN HEALTH (2013)
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients withMetastaticBreast Colorectal and Prostate Cancer
M. Craig Miller et al.
JOURNAL OF ONCOLOGY (2010)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
Steven J. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer
M Cristofanilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
WJ Allard et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
